Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23331063 | 0.80 | PIK3CA (0.43) | PIK3CAPIK3CBPIK3CDPIK3CGPIN1 | |
| SCHEMBL29904748 | 0.75 | ALK (0.43) | PIK3CAPIK3CBPIK3CDPIK3CGPIN1 | |
| SCHEMBL26906772 | 0.75 | ALK (0.43) | PIK3CAPIK3CBPIK3CDPIK3CGPIN1 | |
| SCHEMBL3538817 | 0.74 | TYRO3 (0.34) | JAK2 | |
| SCHEMBL542158 | 0.74 | ALK (0.54) | PIN1GLO1PTGS1PTGS2 | |
| SCHEMBL29435445 | 0.74 | ALK (0.54) | PIN1GLO1PTGS1PTGS2 | |
| SCHEMBL31413266 | 0.72 | KIF11 (0.47) | PIK3CAPIK3CBPIK3CDPIK3CGPIN1 | |
| SCHEMBL20517853 | 0.72 | PIK3CD (0.43) | PIK3CAPIK3CBPIK3CDPIK3CGGLO1 | |
| SCHEMBL26906928 | 0.71 | GLO1 (0.45) | GLO1PTGS1PTGS2 | |
| SCHEMBL1916287 | 0.71 | L3MBTL1 (0.39) | PIK3CAPIK3CBPIK3CDPIK3CGPIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| WO-2021083380-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海科技大学 | 2021-05-06 | — | — | WO | disclosed |
| CN-106687457-B | Heteroaryl compounds for kinase inhibition | 阿里亚德医药股份有限公司 | 2020-01-10 | — | — | CN | disclosed |
| EP-3143015-B1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMA INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3143015-B1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMA INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20170166598-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170166598-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-06-15 | — | — | US | disclosed |
| EP-3143015-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD Pharmaceuticals, Inc. (US) | 2017-03-22 | — | — | EP | disclosed |
| WO-2015175632-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015175632-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP4F11, CYP4A11, HSD11B1 | PIK3CA 2963/4885PIK3CB 4347/4885PIK3CD 2905/4885 |
| US-20170166598-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | PIK3CA 7/4885PIK3CB 34/4885PIK3CD 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.